LOS ANGELES, Sept. 10 Today, Grifols launched in the USits proprietary PediGri(R) On Line system that gives healthcare providersaccess to quality and safety information about the plasma used in theproduction of Grifols' therapies. Through a web portal athttp://www.pedigrionline.net registered healthcare providers (includingphysicians, nurses and pharmacists) can access lot specific information aboutthe individual plasma sources that contributed to each product vial. GrifolsUSA is the US sales and marketing division of Grifols, SA a global healthcarecompany based in Barcelona, Spain that specializes in the production oflife-saving plasma therapies.
The Grifols PediGri(R) system provides full traceability from donation tofinal product. "Today, it is more important than ever that healthcareproviders have confidence in the source of the medications they prescribe andadminister," commented Bill Stopher, President of Grifols USA. "GrifolsPediGri(R) provides an unparalleled level of information about the source andquality of the plasma used to produce Grifols' therapies," continued Mr.Stopher. By simply entering the lot number found on the product vial,healthcare providers can view specific quality and safety information abouteach plasma donation used in the production of that vial, the completecertificate of analysis for the lot, and the package insert. To use thesystem, healthcare providers must register on line athttp://www.pedigrionline.net and obtain a confidential username and passwordprior to accessing the PediGri(R) On Line web portal.
"As a physician who prescribes and administers plasma therapies, I believehealthcare providers will embrace PediGri(R) On Line," said Laurence Logan,MD, Medical Director for Grifols USA. "This level of transparency underscoresGrifols' commitment of quality and safety to the healthcare community,"continued Dr. Logan. Patients who use Grifols' therapies can accessPediGri(R) On Line through consultation with their healthcare provider.
Introduction of PediGri(R) On Line is consistent with the Company's longhistory of providing innovative products and services to healthcare providersand healthcare consumers. In the 1950's Grifols pioneered the process ofextracting blood plasma, called plasmapheresis, which has given rise to thewidespread availability of life-saving plasma therapies. Grifols' PediGri(R)has been available in Europe for nearly a decade and will now be madeavailable for all Grifols' plasma therapies marketed and sold in the US. AllGrifols' therapies marketed and sold in the US are produced exclusively fromplasma obtained at FDA licensed and inspected donor centers located in the US.
Grifols SA (Grifols) is a global healthcare company based in Barcelona,Spain since 1940, that today provides products and services in more than 90countries around the world. Grifols specializes in the production of plasmatherapies to treat a variety of life-threatening diseases and conditions.Grifols operates manufacturing facilities in Barcelona, Spain and Los Angeles,California in addition to 80 FDA licensed and inspected plasma donor centersthroughout the US. For more information about Grifols please visithttp://www.grifols.com
SOURCE Grifols SA